Lawrence Biegelsen
Stock Analyst at Wells Fargo
(0.95)
# 3,663
Out of 4,761 analysts
59
Total ratings
47.06%
Success rate
-12.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lawrence Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Overweight | $305 → $322 | $282.80 | +13.86% | 4 | Feb 21, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $133 → $136 | $134.92 | +0.80% | 4 | Jan 23, 2025 | |
| NPCE NeuroPace | Upgrades: Overweight | $16 → $20 | $13.77 | +45.24% | 7 | Mar 14, 2024 | |
| NVRO Nevro | Maintains: Equal-Weight | $20 → $17 | $5.73 | +196.68% | 10 | Feb 22, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $166 → $82 | $31.00 | +164.52% | 5 | Aug 4, 2022 | |
| TFX Teleflex | Downgrades: Equal-Weight | $248 | $175.64 | +41.20% | 1 | Jul 29, 2022 | |
| BDX Becton, Dickinson and Company | Upgrades: Overweight | $275 | $227.43 | +20.92% | 4 | Jun 24, 2022 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $350 → $339 | $591.79 | -42.72% | 2 | Apr 22, 2022 | |
| REE REE Automotive | Initiates: Underweight | $1.5 | $7.76 | -80.67% | 1 | Mar 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $55 → $27 | $8.96 | +201.34% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $124 → $111 | $104.83 | +5.89% | 2 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $144 | $88.78 | +61.92% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $56 | $125.88 | -55.51% | 4 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $74 | $103.16 | -28.27% | 6 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 | $73.30 | +4.60% | 3 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $85 → $90 | $22.09 | +307.42% | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $80.28 | - | 1 | Dec 12, 2019 |
Insulet
Feb 21, 2025
Maintains: Overweight
Price Target: $305 → $322
Current: $282.80
Upside: +13.86%
Abbott Laboratories
Jan 23, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $134.92
Upside: +0.80%
NeuroPace
Mar 14, 2024
Upgrades: Overweight
Price Target: $16 → $20
Current: $13.77
Upside: +45.24%
Nevro
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $20 → $17
Current: $5.73
Upside: +196.68%
Tandem Diabetes Care
Aug 4, 2022
Maintains: Overweight
Price Target: $166 → $82
Current: $31.00
Upside: +164.52%
Teleflex
Jul 29, 2022
Downgrades: Equal-Weight
Price Target: $248
Current: $175.64
Upside: +41.20%
Becton, Dickinson and Company
Jun 24, 2022
Upgrades: Overweight
Price Target: $275
Current: $227.43
Upside: +20.92%
Intuitive Surgical
Apr 22, 2022
Maintains: Overweight
Price Target: $350 → $339
Current: $591.79
Upside: -42.72%
REE Automotive
Mar 25, 2022
Initiates: Underweight
Price Target: $1.5
Current: $7.76
Upside: -80.67%
Pulmonx
Feb 24, 2022
Maintains: Equal-Weight
Price Target: $55 → $27
Current: $8.96
Upside: +201.34%
Feb 8, 2022
Maintains: Underweight
Price Target: $124 → $111
Current: $104.83
Upside: +5.89%
Jan 19, 2022
Upgrades: Overweight
Price Target: $144
Current: $88.78
Upside: +61.92%
Jan 19, 2022
Upgrades: Equal-Weight
Price Target: $56
Current: $125.88
Upside: -55.51%
Oct 29, 2021
Maintains: Equal-Weight
Price Target: $68 → $74
Current: $103.16
Upside: -28.27%
Apr 28, 2020
Downgrades: Equal-Weight
Price Target: $77
Current: $73.30
Upside: +4.60%
Mar 5, 2020
Upgrades: Overweight
Price Target: $85 → $90
Current: $22.09
Upside: +307.42%
Dec 12, 2019
Upgrades: Overweight
Price Target: n/a
Current: $80.28
Upside: -